EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Effect of Intrauterine Administration of Growth Hormone on IVF Success Rate in Recurrent Implantation Failure Women: A Randomized Clinical Trial

Fatemeh Amirkhanloo, Mohammad Javanbakht, Sarah Lotfi iD, Ghazal Sahraiyan, Razieh Akbari, Elham Feizabad iD, Shima Rahimi iD, Mahbod Ebrahimi, Firouzeh Akbari Asbagh, Fateme Davari Tanha

Iranian Journal of Pharmaceutical Research · 16.12.2024 · 23 (1)

DOI: 10.5812/ijpr-153636 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 16.12.2024. Verfasst von Fatemeh Amirkhanloo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Yas Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The positive effects of growth hormone (GH) on the endometrium, including increased endometrial blood supply and enhanced expression of cytokines associated with endometrial receptivity, have been noted. However, data on the effect of GH on the endometrium remain limited.

Objectives

This study aimed to investigate the effect of intrauterine administration of GH on the IVF success rate in women with recurrent implantation failure (RIF).

Methods

This randomized double-blind clinical trial was conducted on 60 infertile women under 40 years old with a Body Mass Index (BMI) below 30 kg/m², all diagnosed with RIF—defined as at least three failed pregnancies after transferring a minimum of four good-quality embryos due to unknown causes. Women with uterine malformations, Asherman syndrome, cavity-distorting lesions, severe endometriosis, or other underlying diseases were excluded. After six days of estrogen therapy, transvaginal ultrasound (TVS) was performed to measure and compare the thickness and quality of the endometrium. Participants were divided into two groups. In the intervention group, 10 units of GH were administered using an IUI catheter positioned one centimeter above the cervical os. Study outcomes included changes in endometrial thickness (ET) and quality, as well as pregnancy rates. Primary endpoints were changes in ET and quality, while secondary endpoints were pregnancy rates. Adverse drug responses were also evaluated.

Results

The mean age was 34.96 ± 4.04 years, and the mean BMI was 24.89 ± 2.91 kg/m², with no significant differences in baseline variables between the study groups. The average ET on the 8th day of the cycle was 5.38 ± 0.96 mm in the intervention group and 5.20 ± 0.80 mm in the control group, showing no significant difference (P = 0.467). The ET on the day of initiating progesterone was 7.60 ± 1.03 mm in the intervention group and 7.40 ± 0.60 mm in the control group, with no significant difference (P = 0.264). The odds ratio for achieving a high-quality endometrium was 2.37 (95% CI 0.80 - 6.98, P = 0.116) for the GH group compared to the non-GH group. The odds ratio for achieving a clinical pregnancy was 3.06 (95% CI 0.54 - 17.37, P = 0.205) for the GH group compared to the non-GH group. Two cases of cervicitis were reported in the GH group.

Conclusions

Intrauterine administration of GH appears to enhance endometrial receptivity in women with RIF.

Schlagwörter

Stichwörter der Autor:innen

Endometrial ReceptivityGrowth HormoneIntrauterine AdministrationRIF

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Yas Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
  • Nephrology and Urology Research Center, Clinical Science Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Department of Infertility, Qom University of Medical Sciences, Qom, Iran.
  • Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Sarah Lotfi, Elham Feizabad, Shima Rahimi

Zitieren

APA

Amirkhanloo, F., Javanbakht, M., Lotfi, S., Sahraiyan, G., Akbari, R., Feizabad, E., Rahimi, S., Ebrahimi, M., Akbari Asbagh, F., & Davari Tanha, F. (2024). The Effect of Intrauterine Administration of Growth Hormone on IVF Success Rate in Recurrent Implantation Failure Women: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 23(1). https://doi.org/10.5812/ijpr-153636

Vancouver

Amirkhanloo F, Javanbakht M, Lotfi S, Sahraiyan G, Akbari R, Feizabad E, et al. The Effect of Intrauterine Administration of Growth Hormone on IVF Success Rate in Recurrent Implantation Failure Women: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research. 2024;23(1). doi:10.5812/ijpr-153636

BibTeX
@article{Amirkhanloo2024,
  author = {Amirkhanloo, Fatemeh and Javanbakht, Mohammad and Lotfi, Sarah and Sahraiyan, Ghazal and Akbari, Razieh and Feizabad, Elham and Rahimi, Shima and Ebrahimi, Mahbod and Akbari Asbagh, Firouzeh and Davari Tanha, Fateme},
  title = {The Effect of Intrauterine Administration of Growth Hormone on IVF Success Rate in Recurrent Implantation Failure Women: A Randomized Clinical Trial},
  journal = {Iranian Journal of Pharmaceutical Research},
  year = {2024},
  volume = {23},
  number = {1},
  doi = {10.5812/ijpr-153636}
}
Kostenlos starten →